Femasys Announces Pricing of Underwritten Public Offering and Concurrent Private Placement with Gross Proceeds of $4.5 Million

Core Viewpoint - Femasys Inc. has announced a public offering of 3,600,000 shares at $0.85 per share and a concurrent private placement of 1,686,275 shares at the same price for institutional stockholders, with a higher price of $1.02 for certain directors and officers, aiming to raise approximately $4.5 million for various corporate purposes [1][2]. Group 1: Offering Details - The public offering consists of 3,600,000 shares priced at $0.85 each, while the private placement includes 1,686,275 shares sold at $0.85 to institutional stockholders and $1.02 to directors and officers [1]. - The gross proceeds from both offerings are expected to be around $4.5 million before expenses [1]. - Femasys has granted the underwriter a 30-day option to purchase an additional 540,000 shares from the public offering [1]. Group 2: Use of Proceeds - The net proceeds from the offerings will be utilized for expanding commercial efforts, product development, general corporate purposes, capital expenditures, working capital, and administrative expenses [1]. Group 3: Company Overview - Femasys Inc. is focused on women's health, developing minimally invasive, in-office technologies for reproductive health, including products like FemBloc® and FemaSeed® [5]. - The company markets products such as FemVue® for fallopian tube assessment and FemCerv®, an endocervical tissue sampler [5].